India Calls for Mission-Mode Action as Liver Disease and Type-2 Diabetes Surge Among Younger Populations
Key Insights
Union Minister Dr. Jitendra Singh has called for a nationwide mission-mode response to the interconnected rise of liver disease, Type-2 diabetes (search), and metabolic disorders now affecting younger adults and adolescents in India.
Speaking at the third anniversary of the InFLiMeN network, the Minister emphasized that fatty liver, hypertension (search), dyslipidaemia (search), and insulin resistance are closely linked and predispose one another.
India's unique metabolic profile—including genetic predisposition, central obesity, and the "Indian phenotype"—demands locally generated research data rather than reliance on international evidence alone.
Union Minister Dr. Jitendra Singh has issued an urgent call for a mission-mode national response to the rapidly escalating burden of liver disease, Type-2 diabetes (search), and related metabolic disorders in India, warning that these conditions are now being diagnosed at alarmingly younger ages than ever before.
Speaking at the third anniversary of the Liver & Metabolic Disease Network (InFLiMeN) at the Institute of Liver & Biliary Sciences (ILBS) in New Delhi, Dr. Jitendra Singh said liver disease and Type-2 diabetes (search) cannot be viewed as isolated conditions. "India's liver epidemic and the sharp rise in Type-2 diabetes are part of a larger metabolic nexus, with disorders such as fatty liver, hypertension (search), dyslipidaemia (search) and insulin resistance closely interconnected and predisposing one another," the Minister stated.
A Shifting Disease Profile
The Minister underscored that conditions once largely associated with middle-aged and elderly populations are now increasingly being diagnosed among younger adults and even adolescents, making the situation far more serious than before. This changing epidemiological pattern, he noted, demands a corresponding shift from curative healthcare toward prevention, early detection, and lifestyle modification.
Dr. Jitendra Singh said the government's approach aligns with Prime Minister Narendra Modi's sustained emphasis on addressing obesity and lifestyle-related diseases through preventive healthcare and public participation.
India's Unique Metabolic Vulnerability
A central theme of the Minister's address was India's distinctive metabolic profile, which he said makes the population particularly vulnerable. He pointed to the country's genetic predisposition, higher prevalence of central obesity, and a distinct "Indian phenotype" that renders many individuals susceptible to diabetes, fatty liver disease (search), and cardiovascular illnesses—even when their Body Mass Index (BMI) appears relatively low.
"These characteristics reinforce the need for Indian data, Indian research and Indian solutions instead of relying solely on evidence generated elsewhere," Dr. Jitendra Singh said, emphasizing that locally developed medical solutions will provide a stronger foundation for understanding disease patterns and designing effective public health interventions.
Preventable Risk Factors Under Scrutiny
The Minister highlighted that the liver, despite being one of the body's most resilient and regenerative organs, is increasingly under stress from unhealthy dietary habits, inappropriate sleep patterns, stressful behavior, and environmental pollution. He said reducing these preventable risk factors must become an integral part of India's long-term public health strategy.
Technology, Genomics, and Precision Medicine
Welcoming ILBS' efforts in creating a National Liver Biobank, Dr. Jitendra Singh stressed the importance of developing affordable early diagnostic technologies, community-level screening tools, and indigenous biomarkers capable of identifying liver disease before irreversible damage occurs. Such initiatives, he said, complement the government's commitment to making healthcare more affordable, accessible, and prevention-oriented.
The Minister also pointed to India's expanding biotechnology ecosystem, the Genome Mission, and large-scale gene sequencing programs as valuable tools for understanding the country's unique disease profile. "Advances in biotechnology, genomics and Artificial Intelligence are paving the way for precision medicine, enabling treatments tailored to an individual's genetic profile, lifestyle and environmental exposure," he said.
Beyond Science: The Imperative of Behavioral Change
Dr. Jitendra Singh cautioned that scientific progress alone cannot overcome the challenge unless accompanied by widespread public awareness and behavioral change. He called upon medical professionals, researchers, educational institutions, civil society organizations, and the media to work together in promoting scientifically validated health practices while countering misinformation relating to nutrition, obesity, and lifestyle diseases.
The InFLiMeN network, supported by the Department of Science & Technology (search) (DST), seeks to strengthen collaborative research, innovation, early diagnosis, and evidence-based policy interventions to combat the growing burden of liver and metabolic diseases in India. The event was attended by Dr. Vinod Paul, Former Member of NITI Aayog; Dr. Silviane Pied, French Attachée for Scientific and Academic Cooperation; Prof. Mridul Kumar Daga, Vice Chancellor of ILBS; and Prof. Shiv Kumar Sarin, Director of ILBS, alongside leading clinicians, scientists, and researchers from across the country.
Emphasizing that a healthy population is fundamental to the vision of Viksit Bharat 2047, Dr. Jitendra Singh concluded that reducing India's burden of diabetes and fatty liver disease (search) is essential for preserving the productivity, aspirations, and potential of the country's young population.